Literature DB >> 8491013

Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy.

H G Klues1, W C Roberts, B J Maron.   

Abstract

BACKGROUND: The morphological determinants of mitral valve systolic anterior motion (SAM) and obstruction to left ventricular outflow in patients within the broad clinical spectrum of hypertrophic cardiomyopathy (HCM) are not completely understood, particularly the contribution of mitral leaflet length and size. METHODS AND
RESULTS: To clarify this issue, mitral valve specimens from 43 patients with HCM and basal outflow obstruction were used to relate morphometric measurements of leaflet area to certain morphological and functional assessments of left ventricular outflow tract geometry and valvular motion obtained from echocardiograms in the same patients. Twenty-four patients (56%) had mitral valves of normal size (leaflet area < 12.0 cm2) and 19 patients (44%) had enlarged and elongated valves (area > or = 12.0 cm2). Compared with normal-sized mitral valves, the enlarged valves were situated more posteriorly in a larger left ventricular outflow tract (cross-sectional area, 3.3 +/- 1.0 versus 1.9 +/- 0.7 cm2 for normal-sized valves; p < 0.001) and also had greater systolic excursion of the anterior leaflet (16.2 +/- 4.5 versus 13.3 +/- 3.3 mm, p < 0.02), usually with a distinctive sharp-angled bend and localized contact of the leaflet tip with ventricular septum ("typical" SAM); this pattern of SAM was possible because the central and distal portions of the leaflet were relatively free of fibrous thickening. In contrast, normal-sized mitral valves were situated more anteriorally in a smaller left ventricular outflow tract and frequently showed a different mechanism of SAM and subaortic obstruction with relatively limited leaflet motion, absence of a sharp bend, and septal contact involving more substantial portions of the anterior leaflet and contiguous chordae ("atypical" SAM); mitral-septal apposition was effected in large measure by posterior ventricular septal motion. This pattern of SAM was invariably associated with a more diffuse pattern of fibrous thickening.
CONCLUSIONS: Patients with obstructive HCM show patterns of mitral valve SAM that are diverse and determined largely by the interrelation of left ventricular outflow tract geometry, the size and mobility of the mitral leaflets, and the presence and distribution of fibrous thickening.

Entities:  

Mesh:

Year:  1993        PMID: 8491013     DOI: 10.1161/01.cir.87.5.1570

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  26 in total

1.  Systolic anterior motion after mitral valve repair: predicting factors and management.

Authors:  Takashi Miura; Kiyoyuki Eishi; Shiro Yamachika; Kouji Hashizume; Shiro Hazama; Tsuneo Ariyoshi; Shinichiro Taniguchi; Kenta Izumi; Wataru Hashimoto; Tomohiro Odate
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-11-15

Review 2.  The left ventricular outflow in hypertrophic cardiomyopathy: from structure to function.

Authors:  Magdi H Yacoub; Ismail El-Hamamsy; Karim Said; Gehan Magdi; Fatma Abul Enein; Robert George; Alessandra Rossi; Iacopo Olivotto; Franco Cecchi
Journal:  J Cardiovasc Transl Res       Date:  2009-11-26       Impact factor: 4.132

Review 3.  Mitral valve disease--morphology and mechanisms.

Authors:  Robert A Levine; Albert A Hagége; Daniel P Judge; Muralidhar Padala; Jacob P Dal-Bianco; Elena Aikawa; Jonathan Beaudoin; Joyce Bischoff; Nabila Bouatia-Naji; Patrick Bruneval; Jonathan T Butcher; Alain Carpentier; Miguel Chaput; Adrian H Chester; Catherine Clusel; Francesca N Delling; Harry C Dietz; Christian Dina; Ronen Durst; Leticia Fernandez-Friera; Mark D Handschumacher; Morten O Jensen; Xavier P Jeunemaitre; Hervé Le Marec; Thierry Le Tourneau; Roger R Markwald; Jean Mérot; Emmanuel Messas; David P Milan; Tui Neri; Russell A Norris; David Peal; Maelle Perrocheau; Vincent Probst; Michael Pucéat; Nadia Rosenthal; Jorge Solis; Jean-Jacques Schott; Ehud Schwammenthal; Susan A Slaugenhaupt; Jae-Kwan Song; Magdi H Yacoub
Journal:  Nat Rev Cardiol       Date:  2015-10-20       Impact factor: 32.419

Review 4.  Basic mechanisms of mitral regurgitation.

Authors:  Jacob P Dal-Bianco; Jonathan Beaudoin; Mark D Handschumacher; Robert A Levine
Journal:  Can J Cardiol       Date:  2014-07-02       Impact factor: 5.223

5.  Pacing for obstructive hypertrophic cardiomyopathy.

Authors:  L Kappenberger
Journal:  Br Heart J       Date:  1995-02

6.  Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype?

Authors:  Paco E Bravo; Hong-Chang Luo; Iraklis Pozios; Stefan L Zimmerman; Celia Pamela Corona-Villalobos; Lars Sorensen; Ihab R Kamel; David A Bluemke; Richard L Wahl; M Roselle Abraham; Theodore P Abraham
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-06-14       Impact factor: 6.875

Review 7.  Complementary Role of Echocardiography and Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy.

Authors:  Waseem Hindieh; Raymond Chan; Harry Rakowski
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

8.  In vivo measurement of mitral leaflet surface area and subvalvular geometry in patients with asymmetrical septal hypertrophy: insights into the mechanism of outflow tract obstruction.

Authors:  Dae-Hee Kim; Mark D Handschumacher; Robert A Levine; Yun-Sil Choi; Yun Jeong Kim; Sung-Cheol Yun; Jong-Min Song; Duk-Hyun Kang; Jae-Kwan Song
Journal:  Circulation       Date:  2010-09-13       Impact factor: 29.690

Review 9.  Anatomy of the mitral valve apparatus: role of 2D and 3D echocardiography.

Authors:  Jacob P Dal-Bianco; Robert A Levine
Journal:  Cardiol Clin       Date:  2013-04-15       Impact factor: 2.213

10.  Diastolic leading to systolic anterior motion: new technology reveals physiology.

Authors:  Robert A Levine; Ehud Schwammenthal; Jae-Kwan Song
Journal:  J Am Coll Cardiol       Date:  2014-11-03       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.